RT Journal Article
SR Electronic
T1 598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A680
OP A681
DO 10.1136/jitc-2023-SITC2023.0598
VO 11
IS Suppl 1
A1 Gausdal, Gro
A1 Micklem, David R
A1 Blø, Magnus
A1 Rayford, Austin
A1 Alzhanova, Dina
A1 Madeleine, Noëlly
A1 Taverna, Josephine Amalia
A1 Hung, Chia-Nung
A1 Brekken, Rolf A
A1 Chisamore, Michael
A1 Gorcea-Carson, Claudia
A1 Oliva, Cristina
A1 McCracken, Nigel
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A680.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.